Business
Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $31.00 per share. The public offering was upsized from the previously announced size of 4,000,000 shares of its common stock. All shares of common stock are being offered by Nurix. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $139.5 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions. J.P. Morgan, Piper Sandler and Stifel are acting as the joint bookrunning managers for the proposed offering. RBC Capital Markets and Needham & Company are acting as the lead managers for the proposed offering. A registration statement relating to the sale of these securities has been filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at [email protected]; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or via email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or via email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such ...